Document is current
Any future updates will be listed below
-
Authors
Sidky, Ahmed M. https://orcid.org/0000-0001-6306-1079
Melo, Ana Rosa Vieira https://orcid.org/0000-0002-1759-762X
Kay, Teresa T.
Raposo, Mafalda https://orcid.org/0000-0001-6899-0352
Lima, Manuela https://orcid.org/0000-0002-3357-3273
Monckton, Darren G. https://orcid.org/0000-0002-8298-8264
-
Funding
Funding for this research was provided by:
British Council
Egyptian Ministry of Higher Education and Scientific Research
Fundo Regional para a Ciência e Tecnologia
Fundação para a Ciência e a Tecnologia (CEECIND/03018/2018/CP1556/CT0009)
- License Information
-
More Information
Article History
Received: 26 April 2024
Accepted: 12 August 2024
First Online: 8 October 2024
Declarations
:
: All participants were recruited with informed consent for genetic analyses and the study has been approved by the Ethical Board of the University of the Azores (Parecer 01/2021).
: Within the last 36 months Professor Monckton has been a scientific consultant and/or received an honoraria/grants from AMO Pharma, Dyne, F. Hoffman-La Roche, LoQus23, MOMA Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Rgenta Therapeutics, Sanofi, Sarepta Therapeutics Inc, Script Biosciences, Triplet Therapeutics, and Vertex Pharmaceuticals. Professor Monckton also had research contracts with AMO Pharma and Vertex Pharmaceuticals. The other authors have declared no competing interests.
